Perfuse Therapeutics
PrivateLast Round
Series A
Aug 6, 2020
Total Funding Raised
$11M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Perfuse Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in August 2020.
Perfuse Therapeutics is a biopharmaceutical company that develops novel therapies to treat ischemia-induced ocular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Perfuse Therapeutics Comparables
Compare Perfuse Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ocular Therapeutix Inc | 77% | |
| EyePoint, Inc. | 76% | |
| AbbVie | 74% |
For institutional investors. Book with your work email.
Perfuse Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 6, 2020 | ||||
| Seed | Apr 4, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Perfuse Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hatteras Venture Partners | Series A |
| OrbiMed | Series A |
| Catalio Capital Management | Series A |
| Lilly Asia Ventures | Series A |
| Access Biotechnology | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 95% MoM, reaching 9.8K.
- Jun 1, 2026
Grew 21% QoQ, from 14 to 17 employees.
For institutional investors. Book with your work email.
Perfuse Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Perfuse Therapeutics's valuation, stock price, and market status.
Is Perfuse Therapeutics a public or private company?
Perfuse Therapeutics is a private company.
What is the current stock price of Perfuse Therapeutics?
Perfuse Therapeutics is a private company, so its shares have no public market price. Caplight tracks Perfuse Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Perfuse Therapeutics worth (valuation)?
Valuation information for Perfuse Therapeutics is not publicly available.
Can I buy Perfuse Therapeutics stock?
Perfuse Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Perfuse Therapeutics's last funding round?
Perfuse Therapeutics's most recent funding round was Series A on August 6, 2020.
Who are the main investors in Perfuse Therapeutics?
Key investors in Perfuse Therapeutics include Access Biotechnology.
Will Perfuse Therapeutics IPO soon?
No public IPO plans have been announced for Perfuse Therapeutics.
How can I track Perfuse Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Perfuse Therapeutics's shares on secondary markets.